'No competitors to Victoza' though Novo Nordisk keeps watchful eye on Lilly's dulaglutide
This article was originally published in Scrip
Executive Summary
Novo Nordisk sees no serious threat to Victoza's sales growth from any of the approved or upcoming GLP-1 analogs, although it is keeping an eye on Eli Lilly's dulaglutide, the Danish firm's executive vice-president and long-serving CSO Mads Krogsgaard Thomsen told Scrip.